NEW YORK (360Dx) – BioMérieux said this week that its net income for the year was €179.2 million ($189.1 million), or €4.54 per share, up from €110.3 million, or €2.80 per share in 2015. For 2016, its R&D expenses were down 5 percent year-over-year to €238.9 million from €243.6 million. Its SG&A expenses were €529.2 million, up 4 percent from €510.8 million in 2015.

BioMérieux announced additional 2016 financial results in January.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.